SCHEMBL30748936

SCHEMBL30748936

COc1ccc(CNc2nc(Cl)nc3c2C(C)(C)CN3c2ccc(OC3CCCCC3)cc2)cc1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CCNE2 O96020 1/20 0.41
CCNE1 P24864 1/20 0.41
CDK2 P24941 1/20 0.41
TDP1 Q9NUW8 1/20 0.40
CCND3 P30281 1/20 0.37
CDK6 Q00534 1/20 0.37
CTSL P07711 1/20 0.36
PDE4A P27815 1/20 0.35
PDE4B Q07343 1/20 0.35
PDE4C Q08493 1/20 0.35
PDE4D Q08499 1/20 0.35
THRB P10828 1/20 0.35
LMNA P02545 1/20 0.35
TP53 P04637 1/20 0.35
MAPT P10636 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
ESR1 P03372 1/20 0.35
PDE9A O76083 1/20 0.35
APP P05067 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30749001 0.87 TDP1 (0.38) CCNE2CCNE1CDK2TDP1CTSL
SCHEMBL30749065 0.87 PDE4A (0.39) TDP1PDE4APDE4BPDE4CPDE4D
SCHEMBL30748914 0.84 SLC26A6 (0.42) PDE4APDE4BPDE4CPDE4DTP53
SCHEMBL30748721 0.84 CCNE2 (0.43) CCNE2CCNE1CDK2CCND3CDK6
SCHEMBL28088687 0.73 MAPT (0.40) TDP1LMNAMAPT
SCHEMBL30748757 0.72 ALDH1A1 (0.41) CCNE2CCNE1CDK2CTSLLMNA
SCHEMBL31691227 0.71 APP (0.40) CCND3CDK6LMNATP53MAPT
SCHEMBL31691289 0.71 KDM4E (0.41) TP53MAPTRXFP1APP
SCHEMBL30748885 0.69 TNK2 (0.33) APP
SCHEMBL30748965 0.67 PSEN1 (0.41) APP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2025-10-02 US disclosed
EP-4565588-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF Suzhou Keen Therapeutics Co., Ltd. (CN) 2025-06-11 EP disclosed
WO-2023241620-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2023-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF VHL, BRCA1, TERT CCNE2 1733/4885CCNE1 2310/4885CDK2 680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.